



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Kiyoshi NAKAYAMA et al.

Group Art Unit: 1624

RECEIVED

Appl. No: 09/842,234

Examiner: Rao

SEP **2 6** 2002

Filed : April 26, 2001

TECH CENTER 1600/2900

: DRUG EFFLUX PUMP INHIBITOR

INFORMATION DISCLOSURE STATEMENT

Commissioner of Patents and Trademarks Washington, DC 20231

Sir:

For

In accordance with the duty of disclosure under 37 C.F.R. §§ 1.56, 1.97, and 1.98, Applicants hereby bring the following information to the attention of the Examiner in charge of the above-identified application, which includes information cited and discussed in the specification.

JP 57-144264, accompanied by an English language abstract, which is cited and discussed in the specification beginning at page 17;

JP 60-197686, accompanied by an English language abstract, which is cited and discussed in the specification beginning at page 17;

09/25/2002 TSUGGS 000000506955381, which is cited and discussed in the specification beginning at page 180.00 0P

15;

WO 01/30757, which is the publication of PCT/JP00/07565, cited in the specification beginning at the bottom of page 15;

Laura McMurry et al., "Active Efflux of Tetracycline Encoded by Four Genetically Different Tetracycline Resistance Determinants in *Escherichia Coli*", Proc. Natl. Acad. Sci. USA, Vol. 77, No. 7, pp. 3974-3977, (1990), which is cited and discussed in the specification beginning at page 2;

Keith Poole et al., "Multiple Antibiotic Resistance in *Pseudomans Aeruginosa*: Evidence for Involvement of an Efflux Operon", Journal of Bacteriology, Vol. 175, No. 22, pp. 7363-7372 (1993), which is cited and discussed in the specification beginning at page 2;

Keith Poole et al., "Overexpression of the mexC-mexD-oprJ Efflux Operon in nfxB-type Multidrug-Resistant Strains of *Pseudomans Aeruginosa*", Molecular Microbiology, Vol. 21, No. 4, pp. 713-724 (1996), which is cited and discussed in the specification beginning at page 2;

Thilo Köhler et al., "Characterization of MexE-MexF-OprN, a Positively Regulated Multidrug Efflux System of *Pseudomans Aeruginosa*", Molecular Microbiology, Vol. 23, No. 2, pp. 345-354 (1997), which is cited and discussed in the specification beginning at page 2;

Tomoyuki Mine et al., "Expression in *Exherichia Coli* of a New Multidrug Efflux Pump, MexXY, from *Pseudomonas Aeruginosa*", Antimicrobial Agents and Chemotherapy, vol. 43, No. 2, pp. 415-417 (1999), which is cited and discussed in the specification beginning at page 2; and

Daniel T.W. Chu, "Syntheses of 6-Fluoro-7-piperazin-1-yl-9-cyclopropyl-2,3,4,9-tetrahydroisothiazolo[5,4-*b*]quinoline-3,4-dione and 6-Fluoro-7-piperazin-1-yl-9-*p*-fluorophenyl-2,3,4,9-tetrahydroisothiazolo[5,4-*b*]quinoline-3,4-dione [1]", J. Heterocyclic Chem., Vol. 27, pp. 839-843 (1990), which is cited and discussed in the specification beginning at page 163.

Copies of the above-noted documents are enclosed together with a duly completed Form PTO-1449. The Examiner is accordingly requested to consider each of these documents, and to make them of record in this application by initialing in the appropriate spaces on the Form PTO-1449. Applicant respectfully requests that the Examiner include a copy of the initialed Form PTO-1449 with the next communication from the U.S. Patent and Trademark Office.

Applicants note that this disclosure statement is being filed after first action on the merits, but prior to issuance of an office action closing prosecution. Therefore, a check including the amount of \$180.00 is enclosed. However, if the fee is deficient and/or if any additional fee is required for consideration of this disclosure statement, including any

fee under 37 C.F.R. 1.17(p), Applicants hereby authorize that any required fee be charged to Deposit Account No. 19-0089.

Should there be any questions, the Examiner is invited to contact the undersigned at the below listed telephone number.

Respectfully submitted,

Kiyoshi/NAK/AYAMA et al.

Bruce H. Bernstein

Reg. No. 29,027 Jegns 33,094

September 12, 2002 GREENBLUM & BERNSTEIN, P.L.C. 1941 Roland Clarke Place Reston, VA 20191 (703) 716-1191